48 lawsuits against Brilinta patent only in 15 days
Generics of Brilinta(AstraZeneca, ticagrelor), which has been recognized as a next-generation antithrombotic agent followed by Aspirin and Plavix, have attracted vigorous interests of domestic pharmaceutical companies.
A number of companies have joined in the patent lawsuit, in particular, as s...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
